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of predicted c-Myc binding sites in 
the genome and its association with 
histone acetyltransferase complexes 
prompted the authors to speculate 
that c-Myc may induce global his-
tone acetylation (Fernandez et al., 
2003), perhaps allowing Oct3/4 and 
Sox2 to bind to otherwise inacces-
sible sites. Unlike c-Myc, the role of 
Klf4 in reprogramming is more likely 
to be strictly one of transcriptional 
control. Its key contribution to this 
process is probably to downregulate 
the transcription of p53 (Rowland et 
al., 2005), which is known to regu-
late expression of Nanog (Lin et al., 
2005). Repression of p53 also inhib-
its c-Myc-induced apoptotic path-
ways (Zindy et al., 1998), suggesting 
that c-Myc and Klf4 may act recipro-
cally and that a finely tuned balance 
between them could be crucial for 
successful reprogramming.
Not only does the work of Taka-
hashi and Yamanaka (2006) lend 
important insight into the molecu-
lar nature of reprogramming and 
pluripotency, it represents a signifi-
cant step toward a rational approach 
for generating patient-specific ES 
cell lines that could be used either 
as a source of autologous tissue 
for transplantation or for modeling 
different diseases. This method is 
encumbered by neither the logis-
tical constraints nor the societal 
concerns presented by somatic cell 
nuclear transfer. However, practi-
cal application of this approach still 
requires answering questions con-
cerning the incomplete nature of 
the reprogramming observed, the 
constitutive expression of the trans-
genes, and the therapeutic utility 
of cells modified with known onco-
genes and oncogenic viral vectors.
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Memory loss is an early symptom of Alzheimer’s Disease (AD). The findings of Gong et al. 
(2006) now indicate that enhancing the activity of UCH-L1, a ubiquitin hydrolase, alleviates 
the synaptic dysfunction and memory loss associated with a mouse model of AD. This 
work also raises the question of what role UCH-L1 might play in other diseases involving 
protein aggregation, such as Parkinson’s Disease.Understanding the molecular mech-
anism of memory is one of the most 
compelling and complex challenges 
for the next generation of scientists. 
In a paper that appears in this issue, 
Arancio and colleagues identify a 
protein that may participate in both normal memory formation and in the 
type of memory loss characteristic of 
early AD: the enzyme ubiquitin C-ter-
minal hydrolase of the L1 type (UCH-
L1) (Gong et al., 2006). They show 
that administration of a UCH-L1 
fusion protein to supplement endog-Cell 126, Aenous UCH-L1 has a protective effect 
on memory loss in a mouse model of 
AD. Although the authors propose 
that this effect is mediated by a proc-
ess involved in normal memory, there 
is some evidence that UCH-L1 may 
also be involved in a protective path-ugust 25, 2006 ©2006 Elsevier Inc. 655
way that would also be relevant to 
other protein aggregation diseases 
such as Parkinson’s disease (PD).
Two primary factors led the authors 
to focus their efforts on UCH-L1: 
First, UCH-L1 has a putative but 
still undefined role in the ubiquitin-
dependent protein degradation path-
way. Postmortem analysis of human 
brains has shown this pathway to 
be compromised in AD. Sec-
ond, in the sea slug Aplysia, 
the expression of a UCH-L1 
homolog is increased during 
long-term facilitation, which 
is related to synaptic plastic-
ity and learning. The study of 
Gong et al. was designed to 
test the proposal that UCH-
L1 promotes synaptic plastic-
ity and counteracts memory 
loss in AD.
The authors examined long-
term potentiation (LTP), an 
experimental model for mem-
ory that is widely accepted. 
LTP is an electrophysiological 
phenomenon, characteristic 
of intact neural systems, that 
depends on synaptic plastic-
ity. Compromised LTP may 
be a cause of the memory 
loss that occurs early in the 
course of AD. Several lines 
of evidence support the rel-
evance of LTP to AD. LTP 
deficits are observed in trans-
genic mouse models of AD. 
These mice overproduce the 
amyloid-β protein (Aβ), which 
is subsequently deposited in 
the form of amyloid plaques, 
a characteristic feature of AD. These 
mice also exhibit age-dependent 
neurodegeneration and AD-like cog-
nitive deficits. Moreover, in wild-type 
mice the administration of oligomeric 
forms of Aβ compromises LTP (Walsh 
et al., 2002). Elucidating the sequen-
tial relationships between plaque 
formation, deficits in LTP, cognitive 
function, and neuronal cell death is 
critical for the development of break-
through treatments for AD. Gong et 
al. provide a new molecular clue by 
demonstrating that exogenous UCH-
L1 reverses a deficit in LTP that is 
induced by Aβ.
Treatment of hippocampal slices 
with a small-molecule inhibitor of 
UCH-L1 enzymatic activity (Liu et 
al., 2003) produces a deficit in LTP 
(Gong et al., 2006) as does adminis-
tration of oligomeric Aβ. To augment 
endogenous UCH-L1, Gong et al. cre-
ated a recombinant protein in which 
UCH-L1 was fused to the transduc-
tion domain of the HIV-transactivator 
protein (TAT) to promote the internal-
ization of the fusion protein into cells. 
Remarkably, the effect of oligomeric 
Aβ can be reversed by coadminister-
ing a recombinant UCH-L1 protein 
(Gong et al., 2006). Similarly, treat-
ment of transgenic mouse models 
of AD with UCH-L1-TAT restores 
LTP and contextual memory to nor-
mal levels. This treatment decreases 
levels of the regulatory subunit of 
protein kinase A (PKA-RIIα), which, 
in turn, leads to increased levels of 
phosopho-CREB (cAMP response 
element binding protein), a transcrip-
tion factor that promotes synaptic 
plasticity, LTP, and memory (Gong 
et al., 2006). These findings clearly 
demonstrate a link between UCH-
L1 and LTP and suggest that activa-
tion of UCH-L1 may be a therapeutic 
approach to memory loss.
To turn this finding into medicine, 
it is critical to further investigate its 
mechanistic basis. It will be very 
important to determine whether 
UCH-L1 acts to reverse a 
single deleterious effect of 
oligomeric Aβ, or whether it 
could instead act in a more 
global way, by destroying or 
“neutralizing” oligomeric Aβ. 
In the latter scenario all of 
the symptoms of AD that are 
caused by oligomeric Aβ, not 
just memory loss, could be 
targeted by enhancing the 
relevant activity of UCH-L1.
Gong et al. propose that 
UCH-L1 reverses the inhibi-
tory effect of oligomeric Aβ 
on LTP by stimulating protea-
somal degradation of PKA-
RIIα and reducing PKA-RIIα 
to normal levels (Figure 1). 
This model is based, in part, 
on the assumption that UCH-
L1 plays a role in the protea-
somal degradation pathway. 
However, the linkage of UCH-
L1 to the ubiquitin-dependent 
proteasomal pathway is pri-
marily based on its sequence 
homology to UCH-L3 and the 
fact that, in vitro, both are 
capable of hydrolyzing C-ter-
minal conjugates of ubiquitin 
(conjugates of other Ub-like 
proteins may also be substrates). 
Yet, several differences between 
UCH-L1 and UCH-L3 suggest that 
their in vivo activities may be very 
different. For example, in vitro the 
ubiquityl hydrolase activity of UCH-
L1 is much lower than that of UCH-L3 
(Liu et al., 2002; Das et al., 2006). In 
addition, the expression of UCH-L1 
is much higher in terminally differen-
tiated cells, particularly in the brain, 
whereas UCH-L3 is highly expressed 
systemically, including in the brain. 
One could argue that a “backup” 
UCH is required because protea-
somal degradation is more critical 
figure 1. UcH-L1 and Memory Loss in Mouse Models 
of Alzheimer’s Disease
Oligomeric Aβ protein (Αβ42)n has been linked to neurodegen-
eration and plaque formation. Gong et al. propose that UCH-
L1, a ubiquitin C-terminal hydrolase, counteracts the inhibi-
tory effect of oligomeric Aβ on the proteasome by promoting 
protein degradation in general, including the degradation of 
PKA-RIIα. Because increased PKA-RIIα is linked to decreased 
long-term potentiation (LTP), reducing PKA-RIIα would pro-
mote a restoration of normal LTP and cognitive function. In an 
alternative model, UCH-L1 directly promotes the degradation 
or neutralization of oligomeric Aβ, thus restoring the activity of 
the proteasome. The pathway involved may be generalizable 
to other protein aggregates. The link between disruption of LTP 
and neurodegeneration is uncertain. This is a critical question 
that may be addressed using transgenic mouse models.656 Cell 126, August 25, 2006 ©2006 Elsevier Inc.
in postmitotic cells, but it is difficult 
to explain why the absence of UCH-
L1, as seen in the gad (gracile axonal 
dystrophy) mouse, results in neuro-
degeneration, whereas the absence 
of UCH-L3 does not (Saigoh et al., 
1999; Kurihara et al., 2001).
It is possible that UCH-L1 influ-
ences the proteasome pathway but 
by a mechanism unrelated to its 
enzymatic activity. UCH-L1 and an 
enzymatically inactive mutant, C90S, 
both increase free ubiquitin levels 
in cell culture experiments (Osaka 
et al., 2003). But C90S-TAT did not 
rescue the deficit in LTP induced by 
Aβ, making free ubiquitin levels a less 
likely explanation for rescue (Gong 
et al., 2006). In fact, C90S-TAT acted 
as a dominant negative, that is, it 
caused a deficit in LTP in the absence 
of oligomeric Aβ (Gong et al., 2006). 
This striking finding argues that 
C90S inhibits the protective action of 
endogenous UCH-L1, which is hard 
to explain by invoking its hydrolytic 
activity. A final piece of evidence that 
is not easily explained by the model 
proposed by Gong et al. is that, in the 
absence of oligomeric Aβ, UCH-L1-
TAT has no effect on the level of PKA-
RIIα. Thus, the pathway that medi-
ates the effect of UCH-L1-TAT seems 
to be relevant only under conditions 
induced by protein aggregation.
An alternative model (Figure 1) 
proposes that UCH-L1 rescues the 
effect of oligomeric Aβ directly, 
either by promoting its disaggre-
gation, promoting its clearance, or 
“neutralizing” it in some other way. A recent study showed that the levels 
in the brain of one oligomeric Aβ spe-
cies, designated Aβ*56, correlated 
with the severity of memory deficits 
of a transgenic mouse (Lesne et al., 
2006). Direct injection of Aβ*56 into 
a normal mouse induced memory 
deficits, supporting the proposal 
that it could be responsible for 
memory loss. It will be interesting to 
determine whether Aβ*56 levels are 
altered in the brains of mice treated 
with UCH-L1-TAT.
If Aβ*56, for example, is the rele-
vant target of UCH-L1, as opposed 
to PKA-RIIα, then UCH-L1 may 
alleviate neuronal degeneration 
and other phenotypes that charac-
terize full-blown AD. Moreover, one 
might expect that UCH-L1 could 
play a role in other protein aggre-
gation-dependent neurodegenera-
tive diseases, such as PD, that are 
not characterized by early memory 
loss. In fact, a polymorphism in the 
UCH-L1 gene that increases the 
risk of AD in females (Xue and Jia, 
2006) also effects the risk of PD 
in Asian populations (Satoh and 
Kuroda, 2001). Thus, it is possible 
that UCH-L1 is involved in a gen-
eral neuroprotective response to 
protein aggregation, rather than an 
event specific to AD. Irregardless 
of whether enhancing the activity 
of UCH-L1 has its beneficial effect 
in mice by decreasing PKA-RIIα or 
is instead due to a decrease in oli-
gomeric Aβ, UCH-L1 may prove to 
be a useful therapeutic target for 
treating AD.Cell 126, AAcknowLeDgMents
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